Comparative Pharmacology
Head-to-head clinical analysis: ESOMEPRAZOLE MAGNESIUM versus PROTONIX IV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESOMEPRAZOLE MAGNESIUM versus PROTONIX IV.
ESOMEPRAZOLE MAGNESIUM vs PROTONIX IV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase at the secretory surface of gastric parietal cells.
Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells.
20-40 mg orally once daily; for erosive esophagitis, 40 mg once daily for 4-8 weeks. IV: 20-40 mg once daily over 10-30 minutes.
40 mg intravenously once daily for 7-10 days; for pathological hypersecretory conditions, initial dose 80 mg IV every 12 hours, titrate per acid output.
None Documented
None Documented
Terminal elimination half-life is approximately 1–1.5 hours in healthy individuals, but may be prolonged to 2–3 hours in poor metabolizers (CYP2C19) or patients with hepatic impairment. The effect on gastric acid secretion persists for 24 hours due to irreversible binding to proton pumps.
1-2 hours in healthy subjects; prolonged to 3.5-8 hours in hepatic impairment.
Approximately 80% of a dose is excreted as metabolites in urine, with the remainder (about 20%) eliminated in feces via biliary excretion. Less than 1% is excreted unchanged in urine.
Primarily hepatic metabolism; 71-82% of dose excreted in urine as metabolites, 18-20% in feces.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor